Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aptose Bioscns
(NQ:
APTO
)
0.4060
+0.0087 (+2.19%)
Streaming Delayed Price
Updated: 3:43 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptose Bioscns
< Previous
1
2
3
4
5
Next >
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
Via
Benzinga
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Expert Ratings for Aptose Biosciences
September 07, 2023
Via
Benzinga
Analyst Expectations for Aptose Biosciences's Future
May 09, 2023
Via
Benzinga
Canaccord Genuity Maintains Buy Rating for Aptose Biosciences: Here's What You Need To Know
March 27, 2023
Via
Benzinga
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
October 16, 2023
Company to Hold Clinical Update Webcast; Details Forthcoming
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
September 18, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
September 06, 2023
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know
August 11, 2023
Via
Benzinga
Aptose Reports Results for the Second Quarter 2023
August 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
July 27, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
June 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
July 26, 2023
Wednesday saw 59 companies set new 52-week lows.
Via
Benzinga
Aptose Presents Highlights from Clinical Update
June 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Provides Update on Reverse Stock Split
June 05, 2023
Common Shares to begin trading on adjusted basis June 6
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
May 31, 2023
EHA Abstract on Tuspetinib and Venetoclax Recently Published
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Enters into $25 Million Committed Equity Facility
May 25, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
May 24, 2023
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And...
Via
Benzinga
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
3 Stocks With 1,000% Upside Potential
May 21, 2023
If you're an investor comfortable with speculative bets, analysts are price targeting these stocks with 1000% upside.
Via
InvestorPlace
Aptose Reports Results for the First Quarter 2023
May 08, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 04, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
April 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
April 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 28, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2022
March 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 23, 2023
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.